ŠTARK, Tibor, S. DI MARTINO, F. DRAGO, C. T. WOTJAK a V. MICALE. Phytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment. Pharmacological Research. London: ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD, 2021, roč. 174, December 2021, s. 1-15. ISSN 1043-6618. Dostupné z: https://dx.doi.org/10.1016/j.phrs.2021.105938.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Phytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment
Autoři ŠTARK, Tibor (703 Slovensko, domácí), S. DI MARTINO, F. DRAGO, C. T. WOTJAK a V. MICALE (garant).
Vydání Pharmacological Research, London, ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD, 2021, 1043-6618.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30104 Pharmacology and pharmacy
Stát vydavatele Německo
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 10.334
Kód RIV RIV/00216224:14110/21:00124165
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1016/j.phrs.2021.105938
UT WoS 000724713300004
Klíčová slova anglicky THC; Cannabidiol; Adolescence; Schizophrenia; Animal model; Neurodevelopment
Štítky 14110516, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 15. 2. 2022 13:37.
Anotace
The recent shift in socio-political debates and growing liberalization of Cannabis use across the globe has raised concern regarding its impact on vulnerable populations such as adolescents. Concurrent with declining perception of Cannabis harms, more adolescents are using it daily in several countries and consuming marijuana strains with high content of psychotropic delta (9)-tetrahydrocannabinol (THC). These dual, related trends seem to facilitate the development of compromised social and cognitive performance at adulthood, which are described in preclinical and human studies. Cannabis exerts its effects via altering signalling within the endocannabinoid system (ECS), which modulates the stress circuitry during the neurodevelopment. In this context early interventions appear to circumvent the emergence of adult neurodevelopmental deficits. Accordingly, Cannabis sativa second-most abundant compound, cannabidiol (CBD), emerges as a potential therapeutic agent to treat neuropsychiatric disorders. We first focus on human and preclinical studies on the long-term effects induced by adolescent THC exposure as a "critical window" of enhanced neurophysiological vulnerability, which could be involved in the pathophysiology of schizophrenia and related primary psychotic disorders. Then, we focus on adolescence as a "window of opportunity" for early pharmacological treatment, as novel risk reduction strategy for neurodevelopmental disorders. Thus, we review current preclinical and clinical evidence regarding the efficacy of CBD in terms of positive, negative and cognitive symptoms treatment, safety profile, and molecular targets.
Návaznosti
MUNI/A/1249/2020, interní kód MUNázev: Základní výzkum v oblasti farmakokinetiky, neurobiologie závislostí a aplikovaný výzkum v oblasti personalizované farmakoterapie v onkologii (Akronym: SV_Farmakologie2021)
Investor: Masarykova univerzita, Základní výzkum v oblasti farmakokinetiky, neurobiologie závislostí a aplikovaný výzkum v oblasti personalizované farmakoterapie v onkologii
3SGA5789, interní kód MUNázev: PRECIPITATION OF SCHIZOPHRENIA-LIKE PHENOTYPE BY PRENATAL INFLUENCES: ASSESSING THE ROLE OF THE ENDOCANNABINOID SYSTEM (Akronym: ncRNAPain)
Investor: Jihomoravský kraj, PRECIPITATION OF SCHIZOPHRENIA-LIKE PHENOTYPE BY PRENATAL INFLUENCES: ASSESSING THE ROLE OF THE ENDOCANNABINOID SYSTEM, Granty pro zahraniční vědce
VytisknoutZobrazeno: 23. 6. 2024 07:25